A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

December 23, 2020

Primary Completion Date

May 22, 2022

Study Completion Date

December 10, 2023

Conditions
Ovarian Cancer
Interventions
DRUG

Manganese Chloride

Administered by inhalation at 0.4mg/kg twice per week in the first 3-week cycle, and then inhaled 0.4mg/kg twice in the first week of each 3-week cycle thereafter

DRUG

nab-paclitaxel

Administered intravenously, 180-220mg/m2 on day 2 in a 3-week cycle (day 1 without Manganese priming)

DRUG

Platinum chemotherapy

Administered intravenously, Cisplatin (60-80mg/m2) or Carboplatin (area under the curve \[AUC\] 4-6 mg/mL per min) on day 2 in a 3-week cycle (day 1 without Manganese priming)

DRUG

Sintilimab

Administered intravenously, 200mg on day 3 in a 3-week cycle (day 2 without Manganese priming)

Trial Locations (1)

100853

Biotherapeutic Department of Chinese PLA General Hospital, Beijing

All Listed Sponsors
lead

Chinese PLA General Hospital

OTHER

NCT03989336 - A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer | Biotech Hunter | Biotech Hunter